Journal: bioRxiv

Article Title: PTPN1/2 inhibits alveolar macrophage-mediated control of lung metastasis

doi: 10.64898/2026.02.25.707995

Figure Lengend Snippet: A, B. Viability of 4T1 ( A ) and CMT167 ( B ) cells after a 3-day coculture with or without AMs, in the presence of AC484 (50 nM) and/or IFNγ at indicated concentrations (ng/mL). C, D. Comparison of cytokine levels in conditioned medium collected from AMs cocultured with 4T1 ( C ) or CMT167 ( D ) tumor cells, supplemented with AC484 or DMSO controls. Cross makes indicate values beyond the detection range. Cytokines in the 13-plex panel that did not reach the detection limit in either condition were not plotted. E . Viability of 4T1 cells after coculture with or without AMs, comparing direct cell-to-cell contact versus separation by a transwell insert. F . Representative histograms of p-STAT1 (Y701) in AMs from wild-type (WT) or IFNγ knockout (KO) mice after 48 h coculture with CMT167 cells. AMs cultured alone serve as controls. G . Analysis of the fold change in p-STAT1 geometric MFI normalized to non-cocultured AMs from F. H . Viability of CMT167 cells after coculture with or without AMs harvested from WT or IFNγ KO mice, in the presence or absence of AC484. I . Representative histograms of p-STAT1 (Y701) in AMs after 24 h coculture with 4T1 tumor cells, with AC484 (100 nM) and/or the JAK inhibitor ruxolitinib (3 μM). AMs cultured alone with DMSO served as controls. J . Analysis of the fold change in p-STAT1 geometric MFI, normalized to DMSO-treated, non-cocultured control AMs, from experiments in I. K . Viability of 4T1 cells after coculture with or without AMs, in the presence or absence of AC484 (100 nM) and/or ruxolitinib (3 μM). For all bar graphs, data represent individual animals (dots), with mean ± SEM (bars). Unpaired t-test for two-group comparisons; one-way ANOVA for more than two groups: ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.

Article Snippet: In experiments involving the JAK inhibitor ruxolitinib, BAL cells were pre-incubated with ruxolitinib (3 μM, MedChemExpress) in complete RPMI for 2 h, washed, and then cocultured as described, with ruxolitinib maintained throughout the assay at 3 μM.

Techniques: Comparison, Knock-Out, Cell Culture, Control

Journal: Aging Cell

Article Title: Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers

doi: 10.1111/acel.70358

Figure Lengend Snippet: The SASP impacts extent of SC clearance by senolytics. (A) TUNEL‐positive nuclei as a percent of total cells and (B) representative images of surviving (crystal violet + ) senescent preadipocytes and quantification relative to vehicle‐treated cells after exposure to vehicle or Ruxolitinib (1 μM), which attenuates the pro‐inflammatory SASP, for 3 days followed by Dasatinib 800 nM for 24 h. (C) TUNEL‐positive nuclei as a percent of total cells and (D) survival of SCs pre‐treated with 10 μg/mL LPS for 3 days followed by treatment with Dasatinib 800 nM for 24 h. Quantification of images ( N = 5) is shown on the right. Data are shown as means +/− SEM; 1‐way ANOVA; and post hoc comparisons with by Tukey's HSD multiple comparison (A, C), and are expressed as a function of vehicle‐treated cells; means +/− SEM; paired, 2‐tailed Student's t ‐tests.

Article Snippet: The JAK inhibitor Ruxolitinib (tlrl‐rux) was purchased from InvivoGen (Sigma, St. Louis, MO, USA).

Techniques: TUNEL Assay, Comparison